|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- Other contacts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- NHS Regional Offices
- NHS Foundation Trusts (England) - Medical Director
- NHS Foundation Trusts (England) - Chief Executive
- NHS Trusts (England) - Medical Director
- CMO Urgent Messages - Non-NHS Recipients on Public Health Link
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
- Consultants in Communicable Diseases
- CMO Urgent Messages - Recipients on Public Health Link
- Director of Public Health
- NHS Trusts (England) - Chief Executive
- GP - Locum
- NHS 111 and Out of hours providers
- GP Practices
- Out of hours contacts
- Community Pharmacy
- Primary Care Networks
- GP Practices 1
|
| Title: |
|
Neutralising monoclonal antibodies (nMABs) or antivirals for non-hospitalised patients with COVID-19
|
| Broadcast content: |
|
From the 16 December, access to monoclonal antibodies as a treatment for COVID-19 will be extended to non-hospitalised patients who are PCR positive and aged 12 and above who are considered at highest risk of progression to severe disease, hospital admission or death. Eligible patients may receive antiviral therapy if an nMAB is contraindicated. The published interim clinical commissioning policy will be reviewed, if required, as further data emerge on the population prevalence of the omicron variant and any impact on the efficacy of COVID therapies.
|
| Additional information: |
|
NHS England Regional Offices: please cascade to Community Pharmacy
|